Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-κB in cancer cells: Delineation of a novel pathway

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8788-8795

  Mann, Aman P ^a   Verma, Amit ^a   Sethi, Gautam ^a   Manavathi, Bramanandam ^a   Wang, Huamin ^a   Fok, Jansina Y ^a   Kunnumakkara, Ajaikumar B ^a   Kumar, Rakesh ^a   Aggarwal, Bharat B ^a   Mehta, Kapil ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B ALPHA; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; METASTASIS; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; MICROSCOPY, CONFOCAL; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSGLUTAMINASES;

EID: 33748988771     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1457     Document Type: Article

References (46)

1. Lorand L, Graham RM. Transglutaminases: cross-linking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 2003;4:140-56.
2. Mehta K. Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 2005;38:1-18.
3. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 2002;27:534-9.
4. Fesus L, Davies PJ, Piacentini M. Apoptosis: molecular mechanisms in programmed cell death. Eur J Cell Biol 1991;56:170-7.
5. Melino G, Annicchiarico-Petruzzelli M, Piredda L, et al. Tissue transglutaminase and apoptosis: sense and antisense transfection studies with human neuroblastoma cells. Mol Cell Biol 1994;14:6584-96.
6. Oliverio S, Amendola A, Di Sano F, et al. Tissue transglutaminase- dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis. Mol Cell Biol 1997;17:6040-8.
7. Autuori F, Farrace MG, Oliverio S, Piredda L, Piacentini M. "Tissue" transglutaminase and apoptosis. Adv Biochem Eng Biotechnol 1998;62:129-36.
8. Antonyak MA, Singh US, Lee DA, et al. Effects of tissue transglutaminase on retinoic acid-induced cellular differentiation and protection against apoptosis. J Biol Chem 2001;276:33582-7.
9. Antonyak MA, Miller AM, Jansen JM, et al. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem 2004;279:41461-7.
10. Boehm JE, Singh U, Combs C, Antonyak MA, Cerione RA. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem 2002;277:20127-30.
11. Mangala LS, Mehta K. Tissue transglutaminase in cancer. In: Mehta K, Eckert R, editors. Transglutaminases: the family of enzymes with diverse functions. Basel: Karger; 2005. p. 125-38.
12. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004;10:8068-76.
13. Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer 1994;58:400-6.
14. Chen J, Kanopleva M, Multani A, Pathak S, Mehta K. Drug resistant breast cancer MCF-7 cells are paradoxically sensitive to apoptosis. J Cell Physiol 2004;200:223-34.
15. Herman JF, Mangala LS, Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 2006;25:3049-58.
16. Sarang Z, Molnar P, Nemeth T, et al. Tissue transglutaminase acting as G protein protects hepatocytes against Fas-mediated cell death in mice. Hepatology 2005;42:578-87.
17. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
18. Baeuerle PA, Baltimore D. IκB: a specific inhibitor of the NF-κB transcription factor. Science 1988;242:540-6.
19. Nakanish C, Toi M. Nuclear factor-κB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005;5:297-309.
20. Karin M, Cao Y, Greeten FR, Li ZW. NF-κB in cancer; from innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
21. Wang W, Abbruzzese AL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
22. Bours V, Dejardin E, Goujon-Letawe F, Merville MP, Castronovo V. The NF-κB transcription factor and cancer: high expression of NF-κB- and IκB-related proteins in tumor cell lines. Biochem Pharmacol 1994;47:145-9.
23. Sovak MA, Bellas RE, Kim DW, et al. Aberrant nuclear factor-κB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997;100:2952-60.
24. Dejardin E, Bonizzi G, Bellahcene A, Castronovo V, Merville MP, Bours V. Highly expressed p100/p50 (NF-κB2) sequesters other NF-κB-related proteins in the cytoplasm of human breast cancer cells. Oncogene 1995;11:1835-41.
25. Duffey DC, Chen Z, Dong G, et al. Expression of a dominant-negative mutant IκBα of nuclear factor-κB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999;59:3468-74.
26. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge GW, Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17:3629-39.
27. Devarajan E, Chen J, Multani AS, Pathak S, Sahin AA, Mehta K. Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol 2002;20:913-20.
28. Wang H, Zhang W, Fuller GN. Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol 2002;12:95-107.
29. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-7.
30. Chen JS, Agarwal N, Mehta K. Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat 2002;71:237-47.
31. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003;24:1269-79.
32. Joshi S, Guleria R, Pan J, DiPette D, Sing US. Retinoic acid receptors and tissue transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 2006;25:240-7.
33. Han JA, Park SC. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 1999;125:89-95.
34. Jiang D, Ying W, Lu Y, et al. Identification of metastasis-associated proteins by proteomic analysis and functional exploration of interleukin-18 in metastasis. Proteomics 2003;3:724-37.
35. Jiang WG, Ablin R, Douglas-Jones A, Mansel RE. Expression of transglutaminases in human breast cancer and their possible clinical significance. Oncol Rep 2003;10:2039-44.
36. Aggarwal BB. Nuclear factor-κB: the enemy within. Cancer Cell 2004;6:203-8.
37. Bharati AC, Aggarwal BB. Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883-8.
38. Cheng Q, Lee H, Li Y, Parks T, Cheng G. Upregulation of Bcl-xl and Blf as a potential mechanism of chemoresistance which can be overcome by NF-κB inhibition. Oncogene 2000;19:4936-40.
39. Van de Stolpe A, Caldenhoven E, Stade BG, et al. 12-O- tetradecanoylphorbol-13-acetate and tumor necrosis factor-α-mediated induction of intracellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intracellular adhesion molecule-1 promoter. J Biol Chem 1994;269:6185-92.
40. Thomsen LL, Miles DW. Role of nitric oxide in tumor progression: lessons from human tumors. Cancer Metastasis Rev 1998;17:107-18.
41. Helbig G, Christopherson KW, Bhat-Nakshatri P, et al. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem 2003;278:21631-8.
42. Fujioka S, Sclabas GM, Schmidt C, et al. Function of nuclear factor-κB in pancreatic cancer metastasis. Clin Cancer Res 2003;9:346-54.
43. Lee J, Kim YS, Choi DH, et al. Transglutaminase 2 induces nuclear factor-κB activation via a novel pathway in BV-2 microglia. J Biol Chem 2004;279:53725-35.
44. Mishra S, Murphy LJ. The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun 2006;339:726-30.
45. Bohuslav J, Chen LF, Kwon H, Mu Y, Greene WC. p53 induces NF-κB activation by an IκB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1. J Biol Chem 2004;279:26115-25.
46. Douillette A, Bibeau-Poirier A, Gravel SP, et al. The proinflammatory actions of angiotensin II are dependent on p65 phosphorylation by the IκB kinase complex. J Biol Chem 2006;281:13275-84.